Nanoviricides (NNVC) Share-based Compensation (2014 - 2026)
Nanoviricides (NNVC) posted Share-based Compensation of $4882.0 for Q1 2026, up 210.96% sequentially from $1570.0 in Q4 2025, and down 17.51% YoY from $5918.0 in Q1 2025.
Nanoviricides (NNVC) Share-based Compensation (2014 - 2026) Analysis & Trends
Nanoviricides has reported Share-based Compensation for 13 years, with the latest figure at $4882.0 in Q1 2026.
- Quarterly Share-based Compensation fell 17.51% year-over-year to $4882.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191552.0 (up 109.43% YoY) and the FY2025 annual result came in at $162625.0, down 9.12% from the prior year.
- Share-based Compensation climbed to $4882.0 in Q1 2026 per NNVC's latest filing, from $1570.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $146850.0 in Q3 2025 and troughed at $1547.0 in Q4 2024.
- A 5-year average of $41208.6 and a median of $38250.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 95.96% in 2024, then soared 220.98% in 2025.
- Over 5 years, Share-based Compensation stood at $38250.0 in 2022, then changed by 0.0% to $38250.0 in 2023, then plunged by 95.96% to $1547.0 in 2024, then grew by 1.49% to $1570.0 in 2025, then soared by 210.96% to $4882.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4882.0, $1570.0, and $146850.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 4,882.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,882.00 |
| Mar 31, 2026 | 4,882.00 |
| Dec 31, 2025 | 1,570.00 |
| Dec 31, 2025 | 1,570.00 |
| Sep 30, 2025 | 146,850.00 |
| Sep 30, 2025 | 146,850.00 |
| Jun 30, 2025 | 38,250.00 |
| Jun 30, 2025 | 38,250.00 |
| Mar 31, 2025 | 5,918.00 |
| Mar 31, 2025 | 5,918.00 |
| Dec 31, 2024 | 1,547.00 |
| Dec 31, 2024 | 1,547.00 |
| Sep 30, 2024 | 45,750.00 |
| Sep 30, 2024 | 45,750.00 |
| Jun 30, 2024 | 38,250.00 |
| Jun 30, 2024 | 38,250.00 |
| Mar 31, 2024 | 40,590.00 |
| Mar 31, 2024 | 40,590.00 |
| Dec 31, 2023 | 38,250.00 |
| Dec 31, 2023 | 38,250.00 |